RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
-17.44%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$2.12B
AUM Growth
-$643M
(-23%)
Cap. Flow
-$85.3M
Cap. Flow
% of AUM
-4.03%
Top 10 Holdings %
Top 10 Hldgs %
32.59%
Holding
150
New
6
Increased
39
Reduced
39
Closed
16
Top Buys
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$36.4M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$19.4M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$11.5M |
| 4 |
Neurocrine Biosciences
NBIX
|
$10.3M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$9.78M |
Top Sells
| 1 |
AbbVie
ABBV
|
$30.7M |
| 2 |
Molina Healthcare
MOH
|
$23.6M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$17.3M |
| 4 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
$15.1M |
| 5 |
Elanco Animal Health
ELAN
|
$13.1M |
Sector Composition
| 1 | Healthcare | 88.36% |
| 2 | Consumer Staples | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RARX
51
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $13.7M | 0.64% |
750,000
| – | – |
|
52
Heron Therapeutics
HRTX
$201M
| $13.6M | 0.64% |
525,000
| – | – |
|
|
XENT
53
DELISTED
Intersect ENT, Inc
XENT
| $13.1M | 0.62% |
465,000
+5,000
| +1% | +$141K |
|
54
Axogen
AXGN
$735M
| $12.3M | 0.58% |
603,970
+60,496
| +11% | +$1.24M |
|
55
Agilent Technologies
A
$36.5B
| $12.3M | 0.58% |
182,800
+18,700
| +11% | +$1.26M |
|
56
Exelixis
EXEL
$10.2B
| $12.2M | 0.58% |
621,400
+26,400
| +4% | +$519K |
|
57
Zimmer Biomet
ZBH
$20.9B
| $12.2M | 0.58% |
121,025
-110,725
| -48% | -$11.1M |
|
|
CELG
58
DELISTED
Celgene Corp
CELG
| $11.9M | 0.56% |
185,150
-175,250
| -49% | -$11.2M |
|
|
BPMC
59
DELISTED
Blueprint Medicines
BPMC
| $11.5M | 0.54% |
213,658
+13,658
| +7% | +$736K |
|
|
SGEN
60
DELISTED
Seagen Inc. Common Stock
SGEN
| $11.5M | 0.54% |
+202,500
| New | +$11.5M |
|
61
Insmed
INSM
$30.7B
| $11.2M | 0.53% |
850,000
-40,000
| -4% | -$525K |
|
|
IMMU
62
DELISTED
Immunomedics Inc
IMMU
| $11.1M | 0.53% |
780,000
+5,000
| +0.6% | +$71.4K |
|
63
DaVita
DVA
$9.86B
| $11.1M | 0.52% |
215,200
-193,300
| -47% | -$9.95M |
|
64
BioMarin Pharmaceuticals
BMRN
$11.1B
| $11M | 0.52% |
129,000
+4,000
| +3% | +$341K |
|
|
BOLD
65
DELISTED
Audentes Therapeutics, Inc
BOLD
| $10.7M | 0.5% |
500,000
+74,975
| +18% | +$1.6M |
|
66
Assembly Biosciences
ASMB
$183M
| $10.2M | 0.48% |
37,500
-3,333
| -8% | -$905K |
|
67
Q32 Bio
QTTB
$20.4M
| $10.1M | 0.47% |
25,000
-1,111
| -4% | -$447K |
|
|
GBT
68
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $10.1M | 0.47% |
245,000
+95,000
| +63% | +$3.9M |
|
|
EPZM
69
DELISTED
Epizyme, Inc
EPZM
| $9.9M | 0.47% |
1,607,500
+366,247
| +30% | +$2.26M |
|
70
Aclaris Therapeutics
ACRS
$227M
| $9.82M | 0.46% |
1,329,400
+449,400
| +51% | +$3.32M |
|
71
Rigel Pharmaceuticals
RIGL
$742M
| $9.66M | 0.46% |
420,000
+7,500
| +2% | +$173K |
|
|
BHVN
72
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $9.62M | 0.45% |
260,000
| – | – |
|
73
Amicus Therapeutics
FOLD
$2.46B
| $9.58M | 0.45% |
1,000,000
| – | – |
|
74
Puma Biotechnology
PBYI
$253M
| $9.29M | 0.44% |
456,462
-31,138
| -6% | -$634K |
|
75
Travere Therapeutics
TVTX
$1.93B
| $9.05M | 0.43% |
400,000
| – | – |
|